Rimedio Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 02-11-2024
- Paid Up Capital ₹ 0.10 M
as on 02-11-2024
- Company Age 4 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -100.00%
(FY 2023)
- Ebitda -75.00%
(FY 2023)
- Net Worth -400.00%
(FY 2023)
- Total Assets -50.00%
(FY 2023)
About Rimedio Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kaushik Natesan, Prashant Paleja, and Amit Bishnoi serve as directors at the Company.
- CIN/LLPIN
U51909MH2020PTC339123
- Company No.
339123
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2020
- Date of AGM
05 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rimedio Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaushik Natesan  | Director | 26-Mar-2020 | Current |
| Prashant Paleja | Additional Director | 16-Aug-2023 | Current |
| Amit Bishnoi | Additional Director | 26-Mar-2024 | Current |
Financial Performance and Corporate Structure Insights of Rimedio Pharma.
Rimedio Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 100% decrease in profit. The company's net worth observed a substantial decline by a decrease of 400%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rimedio Pharma?
In 2022, Rimedio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Novacare Healthcare Solutions Private LimitedActive 6 years 6 monthsPrashant Paleja is a mutual person
Dhanvanthri Super Speciality Private LimitedActive 1 year 4 monthsKaushik Natesan and Amit Bishnoi are mutual person
- Quromed Lifesciences Private LimitedActive 4 years 8 months
Kaushik Natesan, Prashant Paleja and 1 more are mutual person
- Chethana Pharma Distributors Private LimitedActive 4 years 8 months
Kaushik Natesan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rimedio Pharma?
Rimedio Pharma has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rimedio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rimedio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
